Tag: Myeloid Therapeutics MT-303 research
MT-303: First In Vivo GPC3 Targeting mRNA CAR for HCC – SITC 2024 Oral...
Myeloid Therapeutics, Inc. announced an oral presentation at the Society for Immunotherapy in Cancer (SITC) 2024 annual meeting in Houston, Texas. Dr. Matthew Maurer,...